TY - JOUR
T1 - Impact of acute lymphoblastic leukemia induction therapy
T2 - findings from metabolomics on non-fasted plasma samples from a biorepository
AU - Saito, Toshie
AU - Wei, Yue
AU - Wen, Li
AU - Srinivasan, Chaitanya
AU - Wolthers, Benjamin O.
AU - Tsai, Cheng Yu
AU - Harris, Marian H.
AU - Stevenson, Kristen
AU - Byersdorfer, Craig
AU - Oparaji, Judy April
AU - Fernandez, Christian
AU - Mukherjee, Amitava
AU - Abu-El-Haija, Maisam
AU - Agnihotri, Sameer
AU - Schmiegelow, Kjeld
AU - Showalter, Megan R.
AU - Fogle, Paul W.
AU - McCulloch, Scott
AU - Contrepois, Kevin
AU - Silverman, Lewis B.
AU - Ding, Ying
AU - Husain, Sohail Z.
N1 - Publisher Copyright:
© 2021, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2021/7
Y1 - 2021/7
N2 - Introduction: Acute lymphoblastic leukemia (ALL) is among the most common cancers in children. With improvements in combination chemotherapy regimens, the overall survival has increased to over 90%. However, the current challenge is to mitigate adverse events resulting from the complex therapy. Several chemotherapies intercept cancer metabolism, but little is known about their collective role in altering host metabolism. Objectives: We profiled the metabolomic changes in plasma of ALL patients initial- and post- induction therapy. Methods: We exploited a biorepository of non-fasted plasma samples derived from the Dana Farber Cancer Institute ALL Consortium; these samples were obtained from 50 ALL patients initial- and post-induction therapy. Plasma metabolites and complex lipids were analyzed by high resolution tandem mass spectrometry and differential mobility tandem mass spectrometry. Data were analyzed using a covariate-adjusted regression model with multiplicity adjustment. Pathway enrichment analysis and co-expression network analysis were performed to identify unique clusters of molecules. Results: More than 1200 metabolites and complex lipids were identified in the total of global metabolomics and lipidomics platforms. Over 20% of those molecules were significantly altered. In the pathway enrichment analysis, lipids, particularly phosphatidylethanolamines (PEs), were identified. Network analysis indicated that the bioactive fatty acids, docosahexaenoic acid (DHA)-containing (22:6) triacylglycerols (TAGs), were decreased in the post-induction therapy. Conclusion: Metabolomic profiling in ALL patients revealed a large number of alterations following induction chemotherapy. In particular, lipid metabolism was substantially altered. The changes in metabolites and complex lipids following induction therapy could provide insight into the adverse events experienced by ALL patients.
AB - Introduction: Acute lymphoblastic leukemia (ALL) is among the most common cancers in children. With improvements in combination chemotherapy regimens, the overall survival has increased to over 90%. However, the current challenge is to mitigate adverse events resulting from the complex therapy. Several chemotherapies intercept cancer metabolism, but little is known about their collective role in altering host metabolism. Objectives: We profiled the metabolomic changes in plasma of ALL patients initial- and post- induction therapy. Methods: We exploited a biorepository of non-fasted plasma samples derived from the Dana Farber Cancer Institute ALL Consortium; these samples were obtained from 50 ALL patients initial- and post-induction therapy. Plasma metabolites and complex lipids were analyzed by high resolution tandem mass spectrometry and differential mobility tandem mass spectrometry. Data were analyzed using a covariate-adjusted regression model with multiplicity adjustment. Pathway enrichment analysis and co-expression network analysis were performed to identify unique clusters of molecules. Results: More than 1200 metabolites and complex lipids were identified in the total of global metabolomics and lipidomics platforms. Over 20% of those molecules were significantly altered. In the pathway enrichment analysis, lipids, particularly phosphatidylethanolamines (PEs), were identified. Network analysis indicated that the bioactive fatty acids, docosahexaenoic acid (DHA)-containing (22:6) triacylglycerols (TAGs), were decreased in the post-induction therapy. Conclusion: Metabolomic profiling in ALL patients revealed a large number of alterations following induction chemotherapy. In particular, lipid metabolism was substantially altered. The changes in metabolites and complex lipids following induction therapy could provide insight into the adverse events experienced by ALL patients.
KW - Acute lymphoblastic leukemia
KW - Asparaginase phosphatidylethanolamine
KW - Lipidomics
KW - Metabolomics
KW - Triacylglycerol
UR - http://www.scopus.com/inward/record.url?scp=85108954557&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85108954557&partnerID=8YFLogxK
U2 - 10.1007/s11306-021-01814-2
DO - 10.1007/s11306-021-01814-2
M3 - Article
C2 - 34175981
AN - SCOPUS:85108954557
SN - 1573-3882
VL - 17
JO - Metabolomics
JF - Metabolomics
IS - 7
M1 - 64
ER -